Maternal interleukin-6: Marker of fetal growth and adiposity

Tatjana Radaelli, Jennifer Uvena-Celebrezze, Judi Minium, Larraine Huston-Presley, Patrick Catalano, Sylvie Hauguel-de Mouzon

Research output: Contribution to journalArticlepeer-review


Fetal overgrowth and higher adiposity are hallmarks of pregnancy with maternal obesity and poor glucose tolerance, two conditions associated with decreased maternal insulin sensitivity. In non-pregnant individuals, adipokines, vasoactive peptides, and components of the immune system crosstalk with metabolic factors to generate signals triggering obesity and impaired insulin action. We have investigated circulating maternal and fetal cytokines and growth-factors as potential biochemical markers of fetal adiposity. Mothers and neonates were classified into three tertiles (T1-T3) using total neonatal fat mass as the outcome with 309 ± 25 g in T1, 478 ± 40 g in T2, and 529 ± 39 g in T3. Umbilical cord endothelin-1 (ET-1), C-peptide, and leptin were higher in T3 and T2 versus T1. Only cord leptin was strongly associated with fetal fat mass (P

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalJournal of the Society for Gynecologic Investigation
Issue number1
Publication statusPublished - Jan 2006


  • Cytokines
  • Fetal adiposity
  • Growth factors
  • Obesity
  • Pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Maternal interleukin-6: Marker of fetal growth and adiposity'. Together they form a unique fingerprint.

Cite this